What is Oncoustics?
Oncoustics is at the forefront of developing advanced AI and machine learning solutions tailored for point-of-care diagnostics. The company's core focus lies in the non-invasive surveillance and monitoring of liver diseases. By leveraging standard ultrasound devices, Oncoustics' suite of applications empowers clinicians to conduct rapid and cost-effective liver diagnostics. This technological advancement aims to significantly enhance patient access to care and improve their overall experience, ultimately leading to better clinical outcomes through earlier detection and more streamlined healthcare workflows. The company actively collaborates with international clinical partners to validate its technology and broaden its application scope within the global healthcare sector.
How much funding has Oncoustics raised?
Oncoustics has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2022): $5M with participation from Saltagen Ventures and Creative Ventures
Key Investors in Oncoustics
Saltagen Ventures
Saltagen Ventures is an investment firm focused on empowering early-stage deep biotechnology startups, with a specialization in identifying and scaling high-growth potential bioscience technology firms. They actively invest from seed to Series B and collaborate closely with founders to drive successful exits.
Creative Ventures
Creative Ventures is an investment entity that has participated in this funding round. Further details on their specific investment focus are not publicly available.
What's next for Oncoustics?
The recent major strategic investment positions Oncoustics for significant scaling and further technological development. This capital infusion is expected to accelerate the company's go-to-market strategy, expand its clinical validation efforts, and potentially broaden its diagnostic capabilities beyond liver diseases. As Oncoustics continues to mature, it is likely to explore further rounds of financing to support its ambitious growth trajectory and solidify its market position in the competitive landscape of AI-powered medical diagnostics. The company's focus on non-invasive, accessible diagnostics aligns with global healthcare trends, suggesting a strong potential for future expansion and adoption.
See full Oncoustics company page
